01—Abstract
Summary
Summary of the 10-Q filed October 30, 2025. Cited figures are marked; the original filing is the authoritative source.
Biogen Inc. reported solid financial results for the third quarter and first nine months of 2025, demonstrating revenue growth driven by key product lines.
Total revenue increased by 2.8% year-over-year to $2.53 billiona for the quarter, with product revenue showing a 4.4% increase to $1.85 billion. This growth was primarily fueled by the Rare Disease segment, up 7.8%, and a 0.7% increase in Multiple Sclerosis (MS) revenue, with VUMERITY and TYSABRI showing particular strength, despite continued generic competition for TECFIDERA. The company also saw substantial growth in its Alzheimer's collaboration revenue, up 129.6% year-over-year, reflecting increased sales of LEQEMBI.
Despite revenue growth, the company faced increased costs, notably in Cost of Sales, up 5.6%b driven by a litigation charge and higher SKYCLARYS inventory step-up amortization. However, Research and Development (R&D) expenses decreased by 15.5%, partly due to cost-saving measures and R&D funding from Royalty Pharma, while Selling, General, and Administrative (SG&A) expenses saw a modest increase to support product launches.
Diluted earnings per share (EPS) rose by 19.2% to $3.17c, reflecting the revenue growth and improved R&D efficiency. Biogen's liquidity remains strong, with cash, cash equivalents, and marketable securities increasing to $4.0 billion.
02—Key points
Key Highlights
- Total revenue increased by 2.8% to $2.53 billion for Q3 2025, driven by product revenue growth.
- Rare Disease segment revenue grew by 7.8%, bolstered by new product launches like SKYCLARYS and QALSODY.
- Alzheimer's collaboration revenue surged by 129.6% due to increased LEQEMBI sales.
- Diluted Earnings Per Share (EPS) grew by 19.2% to $3.17.
- Research and Development (R&D) expenses decreased by 15.5%, aided by cost-saving initiatives and external funding.
- Cash, cash equivalents, and marketable securities increased to $4.0 billion, indicating strong liquidity.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2025filed October 30, 2025Financial Statements
Q3 FY2025 against Q3 FY2024
| Line item | Q3 FY2025Q3 FY2024 | Change |
|---|---|---|
| Revenue | $2.53B$2.47B | +2.8% |
| Cost of Revenue | $674.40M$638.70M | +5.6% |
| Gross Profit | $1.86B$1.83B | +1.8% |
| SG&A Expenses | $594.80M$588.40M | +1.1% |
| Operating Expenses | $1.98B$2.01B | −1.9% |
| Interest Expense | $67.40M$59.80M | +12.7% |
| Net Income | $466.50M$388.50M | +20.1% |
| EPS (Basic) | $3.18$2.67 | +19.1% |
| EPS (Diluted) | $3.17$2.66 | +19.2% |
| Shares Outstanding (Basic) | 146.60M145.70M | +0.6% |
| Shares Outstanding (Diluted) | 147.10M146.10M | +0.7% |
05—Questions
Frequently Asked Questions
What was the primary driver of Biogen's revenue growth in Q3 2025?
Biogen's revenue growth in Q3 2025 was primarily driven by its Rare Disease segment, which saw a 7.8% increase, and a 4.4% rise in overall product revenue. The strong performance of VUMERITY and TYSABRI within the Multiple Sclerosis segment, along with significant growth in Alzheimer's collaboration revenue from LEQEMBI, also contributed significantly.
How did Biogen manage its expenses in the quarter?
While Cost of Sales increased due to a litigation charge and higher amortization costs, Biogen successfully reduced Research and Development (R&D) expenses by 15.5%. This reduction was attributed to cost-saving measures, portfolio prioritization, and R&D funding from Royalty Pharma. Selling, General, and Administrative (SG&A) expenses saw a slight increase to support product launches.
What is the company's financial position regarding cash and debt?
Biogen's financial position remains robust, with cash, cash equivalents, and marketable securities increasing to $4.0 billion as of September 30, 2025. The company also managed its debt effectively, redeeming its 4.050% Senior Notes due September 15, 2025, with proceeds from its 2025 Senior Notes issuance.
What impact did new product launches and collaborations have on the results?
New product launches like SKYCLARYS and QALSODY contributed significantly to the Rare Disease segment's growth. The Alzheimer's collaboration with Eisai for LEQEMBI showed substantial revenue growth, indicating a successful commercial launch and increasing market penetration.
06—Continue